Outcomes of Clostridium difficile-Associated Disease Treated With Metronidazole or Vancomycin Before and After the Emergence of NAP1/027
The American Journal of GastroenterologyPublished 1 December 2007
Jean‐Louis Pépin, Louis Valiquette, Sandra Gagnon, Sophie Routhier, Isabel Brazeau
Citations174
SJR quartileQ1
SJR score2.34
SNIP2.27
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Loss of superiority of vancomycin over metronidazole coincided with the emergence of NAP1/027, which might be such that the disease follows its natural course.
Abstract
Loss of superiority of vancomycin over metronidazole coincided with the emergence of NAP1/027. Toxin hyperproduction by NAP1/027 might be such that the disease follows its natural course. Novel therapeutic approaches are needed. The higher risk of recurrence in 2003-2004 probably reflected reinfections rather than relapses.
Keywords
Medicine
New England Journal of MedicineAn Epidemic, Toxin Gene–Variant Strain of <i>Clostridium difficile</i>
1,993 Citations2005L. Clifford McDonald, George Killgore +6 more
A previously uncommon strain of C. difficile with variations in toxin genes has become more resistant to fluoroquinolones and has emerged as a cause of geographically dispersed outbreaks of C.'s Difficile-associated disease.
New England Journal of MedicineA Predominantly Clonal Multi-Institutional Outbreak of<i>Clostridium difficile</i>–Associated Diarrhea with High Morbidity and Mortality
1,945 Citations2005Vivian G. Loo, Louise Poirier +17 more
A strain of C. difficile that was resistant to fluoroquinolones and had binary toxin and a partial deletion of the tcdC gene was responsible for this outbreak ofC.difficile-associated diarrhea.
The LancetToxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe
1,428 Citations2005Michel Warny, Jean‐Louis Pépin +6 more
The severity of C difficile-associated disease caused by NAP1/027 could result from hyperproduction of toxins A and B, and dissemination of this strain in North America and Europe could lead to important changes in the epidemiology of C diffusion disease.
New England Journal of MedicineClostridium difficile Colitis
1,331 Citations1994Ciarán P. Kelly, Charalabos Pothoulakis +1 more
Canadian Medical Association JournalClostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity
1,118 Citations2004Jean‐Louis Pépin
An epidemic of CDAD with an increased case-fatality rate has had important consequences on the elderly population of Quebec and the equivalence of vancomycin and metronidazole in the treatment ofCDAD needs to be questioned.
The LancetAssociation between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea
798 Citations2001Lorraine Kyne, Michel Warny +2 more
A serum antibody response to toxin A, during an initial episode of C. difficile diarrhoea, is associated with protection against recurrence, and this response isomersally associated with higher concentrations of serum IgM against toxin A.
The LancetPROSPECTIVE RANDOMISED TRIAL OF METRONIDAZOLE VERSUS VANCOMYCIN FOR CLOSTRIDIUM-DIFFICILE-ASSOCIATED DIARRHOEA AND COLITIS
788 Citations1983DavidG. Teasley, MaryM. Olson +5 more
Metronidazole and vancomycin have equivalent efficacy and relapse rates and are tolerated to a similar extent by patients with C-difficile-related diarrhoea and colitis, but metronidrazole is considerably more economical.
Infection Control and Hospital EpidemiologyRecommendations for Preventing the Spread of Vancomycin Resistance
776 Citations1995
American Journal of Infection ControlRecommendations for preventing the spread of vancomycin resistance: Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC)
711 Citations1995
A rapid increase in the incidence of infection and colonization with vancomycin-resistant enterococci (VRE) has been reported from U.S. hospitals in the last 5 years, and the lack of available antimicrobials for therapy of infections due to VRE poses several problems.
Canadian Medical Association JournalMortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec
608 Citations2005Jean‐Louis Pépin
A high attributable mortality among elderly patients with CDAD mostly caused by a hypervirulent strain is documented, which represents a dramatic change in the severity of this infection.
Annals of Internal MedicineNarrative Review: The New Epidemic of <i>Clostridium difficile</i>–Associated Enteric Disease
592 Citations2006John G. Bartlett
Clostridium difficile is the most common identifiable bacterial cause of diarrhea in the United States and the most sensitive diagnostic test, but the enzyme immunoassay is now used by most laboratories because of ease of processing, cost, and speed of results.
Clinical Infectious DiseasesIncreasing Risk of Relapse after Treatment of Clostridium difficile Colitis in Quebec, Canada
573 Citations2005Jean‐Louis Pépin, M.-E. Alary +6 more
There was an increase in the proportion of patients with CDAD believed, by their attending physicians, to have experienced metronidazole treatment failure, as well as an increased in the frequency of post-metronidrazole therapy recurrences, especially among elderly persons in 2003-2004.
Clinical Infectious DiseasesComparison of Vancomycin, Teicoplanin, Metronidazole, and Fusidic Acid for the Treatment of Clostridium difficile--Associated Diarrhea
509 Citations1996C. Wenisch, Bernhard Parschalk +3 more
The findings suggest that metronidazole is the drug of choice for C. difficile-associated diarrhea and that glycopeptides should be reserved for patients who cannot tolerate metronIDazole or who do not respond to treatment with this drug.
PubMedGuidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee.
452 Citations1997Robert Fekety
These guidelines are developed under the auspices of the American College of Gastroenterology and its Practice Parameters Committee and may be updated with pertinent scientific developments at a later time.
Annual Review of Medicine<i>Clostridium difficile</i> Infection
419 Citations1998Ciarán P. Kelly, J. Thomas LaMont
Diarrhea and colitis usually improve within three days after a patient starts taking metronidazole or vancomycin, but 20% suffer a relapse of diarrhea when these agents are discontinued.
Cochrane Database of Systematic ReviewsAntibiotic treatment for <i>Clostridium difficile</i>-associated diarrhoea in adults
369 Citations2017Richard L. Nelson, Katie J. Suda +1 more
Teicoplanin may be more effective than vancomycin for achieving a symptomatic cure and fidaxomicin was found to be moreeffective than metronidazole for achieving symptomatic Cure in antibiotic treatment for C. difficile infection.
Annals of Internal MedicineTreatment of Asymptomatic <i>Clostridium difficile</i> Carriers (Fecal Excretors) with Vancomycin or Metronidazole
363 Citations1992Stuart Johnson, Scott R. Homann +5 more
GutFaecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile.
324 Citations1986R.P. Bolton, M A Culshaw
The clinical experience of oral metronidazole being effective in the treatment of antibiotic associated diarrhoea caused by C difficile colitis is supported and a potential role for intravenous metronIDazole in this disease is suggested.
GutIntravenous immunoglobulin therapy for severe <i>Clostridium difficile</i> colitis
265 Citations1997José R. Salcedo, Sarah Keates +5 more
BMJRandomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea.
253 Citations1978M R B Keighley, D. W. Burdon +8 more
It is suggested that vancomycin eliminates toxin-producing Cl difficile from the colon and is associated with rapid clinical and histological improvement in patients with pseudomembranous colitis.
Clinical Infectious DiseasesNitazoxanide for the Treatment of Clostridium difficile Colitis
247 Citations2006Daniel M. Musher, Nancy Logan +5 more
Nitazoxanide is at least as effective as metronidazole in treating C. difficile colitis, according to a prospective, randomized, double-blind study.
Clinical Infectious DiseasesTolevamer, a Novel Nonantibiotic Polymer, Compared with Vancomycin in the Treatment of Mild to Moderately Severe Clostridium difficile-Associated Diarrhea
204 Citations2006Thomas Louie, Jennifer Peppe +11 more
Tolevamer, a novel polystyrene binder of C. difficile toxins A and B, effectively treats mild to moderate C.difficile diarrhea and merits further clinical development.
Diseases of the Colon & RectumIntravenous Immunoglobulin for the Treatment of Severe, Refractory, and Recurrent Clostridium difficile Diarrhea
203 Citations2006Stuart McPherson, Colin Rees +3 more
Intravenous immunoglobulin may be effective for severe, refractory, or recurrent Clostridium difficile diarrhea after failed conventional treatment.
Journal of Antimicrobial ChemotherapyDescriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea
200 Citations2004Mark H. Wilcox
Intravenous immunoglobulin is useful for the treatment of intractable and severe CDD and controlled studies are needed to assess the true value of this and other forms of passive immunotherapy.
Clinical Infectious DiseasesA Portrait of the Geographic Dissemination of the Clostridium difficile North American Pulsed-Field Type 1 Strain and the Epidemiology of C. difficile-Associated Disease in Quebec
198 Citations2006Bruno Hubert, Vivian G. Loo +6 more
This study helped to quantify the impact of strain NAP1 on the incidence and severity of C. difficile-associated disease in Québec in 2005 and identified the geographic dissemination of this predominant strain to help to focus regional infection-control efforts.
American Journal of Infection ControlClinical outcomes of intravenous immune globulin in severe clostridium difficile-associated diarrhea
146 Citations2007Paul Juang, Susan J. Skledar +6 more
This study, although limited by a small sample size, does not support the use of IVIG at this dose for severe CDAD outside of a controlled trial.
Emerging infectious diseases<i>Clostridium difficile</i>Ribotype 027, Toxinotype III, the Netherlands
138 Citations2006Ed J. Kuijper, Renate J. van den Berg +7 more
Outbreaks due to Clostridium difficile polymerase chain reaction (PCR) ribotype 027, toxinotype III, were detected in 7 hospitals in the Netherlands from April 2005 to February 2006.
VaccineActive and passive immunization against Clostridium difficile diarrhea and colitis
120 Citations2003Paul J. Giannasca, Michel Warny
Immunological approaches for the management of C. difficile disease are being developed which could reduce the reliance on antibiotics for treatment and allow for re-establishment of the natural barrier provided by an intact commensal flora.
Antimicrobial Agents and ChemotherapyIn Vitro and In Vivo Activities of Nitazoxanide against <i>Clostridium difficile</i>
109 Citations2000Catherine S. McVay, Rial D. Rolfe
The hamster model of antibiotic-inducedClostridium difficile intestinal disease was used to evaluate nitazoxanide (NTZ), a nitrothiazole benzamide antimicrobial agent, and the in vitro and in vivo activities of NTZ in the adult hamster were examined and compared to those of metronidazole and vancomycin.
ChemotherapyIn vitro Activity of Rifaximin, Metronidazole and Vancomycin against <i>Clostridium difficile</i> and the Rate of Selection of Spontaneously Resistant Mutants against Representative Anaerobic and Aerobic Bacteria, Including Ammonia-Producing Species
105 Citations2000Anna Marchese, Angelo Salerno +3 more
The low toxicity, broad antibacterial activity and very poor absorption from the gastrointestinal tract of rifaximin suggest a potential therapeutic use for this drug in gastrointestinal diseases, as well as in the management of patients with cirrhosis and chronic portal-systemic encephalopathy.
Digestive Diseases and SciencesImpact of aging on gastrointestinal mucosal immunity
87 Citations1996Douglas L. Schmucker, Martin F. Heyworth +2 more
The significant age-related increases in the incidence and severity of gastrointestinal infectious diseases, coupled with the potential for immunopharmacologic manipulation of the mucosal immune compartment, substantiate the merit of studies designed to resolve the etiology of mucosal immunodeficiency in the elderly.
Antimicrobial Agents and ChemotherapyIn Vitro Activity of Ramoplanin against <i>Clostridium difficile</i> , Including Strains with Reduced Susceptibility to Vancomycin or with Resistance to Metronidazole
84 Citations2005Teresa Peláez, Luís Alcalá +5 more
In vitro activity of ramoplanin, an antimicrobial compound that inhibits cell wall synthesis by acting at the level of lipid intermediate formation, against Clostridium difficile, was evaluated to assess the potential utility of ram planets for the treatment of C. difficiles-associated diarrhea.
Canadian Medical Association JournalClostridium difficile infection in hospitals: a brewing storm
55 Citations2004Louis Valiquette
The magnitude of this outbreak needs to be better delineated, but clearly something unusual is happening, and it is essential that the authors learn why.
Biophysical JournalToxin Binding of Tolevamer, a Polyanionic Drug that Protects against Antibiotic-Associated Diarrhea
49 Citations2004William H. Braunlin, Qiuwei Xu +5 more
The binding activity of tolevamer reported here correlates well with previously reported results for the inhibition of the biological activity of C. difficile toxins A and B.
Weekly releases (1997–2007)Emergence of Clostridium difficile toxinotype III, PCR-ribotype 027-associated disease, France, 2006
45 Citations2006B. Coignard, Frédéric Barbut +6 more
On 27 March 2006, the Institut de Veille Sanitaire (InVS) was alerted to a cluster of Clostridium difficile associated disease (CDAD) in a healthcare facility in northern France.
Journal of Antimicrobial ChemotherapyComparison of two oral formulations of vancomycin for treatment of diarrhoea associated with <i>Clostridium difficile</i>
30 Citations1989D. R. Baird
Current MicrobiologySusceptibility, resistance development, and synergy of antimicrobial combinations againstClostridium difficile
19 Citations1982P. W. Ensminger, Frederick T. Counter +2 more
Rifampin in combination with erythromycin, methicillin, or penicillin was synergistic against more than 90% of theC.
Weekly releases (1997–2007)Epidemiology of Clostridium difficile toxinotype III, PCR-ribotype 027 associated disease in Belgium, 2006
12 Citations2006Michel Delmée, I. Ramboer +2 more
As a result of the reports of outbreaks of diarrhoea due to Clostridium difficile North American Pulse field type 1, PCR ribotype 027, toxinotype III in North America, United Kingdom, the Netherlands and Belgium, two different surveillance systems were set up in Belgium.